logo-education
0370 270 6000

already registered?

Please sign in with your existing account details.

need to register?

Register to access exclusive content, sign up to receive our updates and personalise your experience on brownejacobson.com.

Privacy statement - Terms and conditions

Forgotten your password?

Thinktank welcomes introduction of PRP

3 January 2014

The Policy Exchange has welcomed the introduction of performance related pay (PRP), arguing that opposition to the reforms is misguided. It believes schools now have the flexibility to reward and retain the best teachers, and allows teachers the ability to progress more quickly, potentially reaching £70k after just five years. The NASUWT have come out against the report, arguing that the new system is based on excessive managerial discretion and is designed to pay all teachers less, rather than good teachers more.

Ultimately, the success of PRP will depend on schools implementing well designed, transparent pay systems which measure the contributions teachers make in all spheres of school life, and on schools having the ability to reward their teachers where merited. Here there is consensus between The Policy Exchange and the NASUWT - that PRP should not be used to hold down the overall pay bill. The best schools will be the ones who can incentivise and reward excellence on a limited budget.

Related opinions

Does the move into Step 4 mean the ending of Covid-19 restrictions within schools?

With the Prime Ministers announcement that he intends for Step 4 to begin on 19 July, this will also bring an end to the restrictions currently in place on education settings.

View blog

Advocacy in Action: Female Genital Mutilation Protection Orders (FGMPO)

The issue of Female Genital Mutilation Protection Orders and the importance of education providers to act promptly.

View blog

Responsibilities towards students identifying as non-binary

Our top tips for supporting transgender and non-binary pupils.

View blog

Schools face scrutiny over Covid-19 vaccinations for children

On 4 June, the Medicines and Healthcare products Regulatory Agency (MHRA) approved the use of the Pfizer/BioNTech Covid-19 vaccine for 12- to 15-year-olds.

View blog

Mailing list sign up

Select which mailings you would like to receive from us.

Sign up